Introduction
============

Over the past two decades, gemcitabine had been the only first-line (1L) chemotherapeutic agent for treatment of advanced pancreatic ductal adenocarcinoma (PDAC) that has proven clinical benefit and modest improvement in survival compared with fluorouracil (5-FU) \[[@b1-crt-2019-190]\]. Recently, combination therapies such as FOLFIRINOX (5-FU, folinic acid, irinotecan, and oxaliplatin) and *nab*-paclitaxel plus gemcitabine (*nab*-P+GEM) have conferred superior outcomes compared with gemcitabine monotherapy. They have become the latest 1L treatments for metastatic PDAC (mPDAC) \[[@b2-crt-2019-190],[@b3-crt-2019-190]\]. Nonetheless, the disease in most patients eventually progresses despite new 1L therapy, and the prognosis remains dismal. The median overall survival (OS) of patients with mPDAC is less than 1 year \[[@b4-crt-2019-190]\].

Improved efficacy of 1L chemotherapy may, however, afford a greater chance for patients with mPDAC to receive subsequent second-line (2L) chemotherapy. Innovations in 1L chemotherapy, with attendant changes in their efficacy and safety profiles, may increase the possibility of achieving benefit from subsequent 2L therapy. Establishment of optimal sequences of effective chemotherapy regimens is needed to improve the overall clinical outcomes of patients with mPDAC in the era of modern 1L regimens.

Currently, *nab*-P+GEM is a standard, widely used 1L regimen for mPDAC \[[@b4-crt-2019-190],[@b5-crt-2019-190]\]. For patients whose cancer progresses on 1L *nab*-P+GEM, fluoropyrimidine-based regimens, including fluoropyrimidine monotherapy, combined fluoropyrimidine and oxaliplatin, and liposomal irinotecan (nal-IRI) plus 5-FU and leucovorin (LV), are recommended as 2L therapy in multiple guidelines \[[@b6-crt-2019-190]-[@b8-crt-2019-190]\]. These recommendations, however, were based on the results of earlier prospective studies \[[@b9-crt-2019-190]-[@b11-crt-2019-190]\] that were conducted prior to the introduction of 1L *nab*-P+GEM. Since then, 2L chemotherapy after progression on 1L *nab*-P+GEM has been rarely investigated.

We therefore retrospectively analyzed clinical outcomes of 2L chemotherapy in patients with mPDAC that had progressed on 1L *nab*-P+GEM.

Materials and Methods
=====================

1. Patients and materials
-------------------------

Between February and December 2016, 203 patients were treated with 1L *nab*-P+GEM for recurrent or metastatic pancreatic cancer at Asan Medical Center, Seoul, Korea, as previously reported \[[@b12-crt-2019-190]\]. The treatment was continued until disease progression, unacceptable toxicity, or patient or physician preference. For the current analysis, we retrospectively reviewed 120 patients who received 2L chemotherapy after disease progression on 1L *nab*-P+GEM. Data collected from the medical records included clinical characteristics at the time 2L treatment was begun, including age, Eastern Cooperative Oncology Group performance status, number of metastatic sites, sites of metastasis, and levels of carbohydrate antigen 19-9 and albumin. The neutrophil, lymphocyte, and platelet counts were used to calculate neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR).

2. Assessment of treatment and response
---------------------------------------

The 2L chemotherapy regimen for each patient was chosen at the discretion of the attending physicians. During 2L therapy, computed tomography or magnetic resonance imaging was performed every 6 to 8 weeks, with additional imaging if disease progression was suspected or unexpected symptoms arose. Tumor response was graded according to the Response Evaluation Criteria in Solid Tumors ver. 1.1.

3. Statistical analysis
-----------------------

Qualitative or categorical variables are presented as frequency and proportion and were compared using the chi-square test or Fisher exact test, as appropriate. Continuous variables, presented as median with 95% confidence interval (CI) or range, were compared using the t test. Overall response rate (ORR) was defined as the proportion of patients who had a partial or complete response to 2L therapy. The disease control rate (DCR) was a composite of ORR and stable disease.

OS with 2L treatment (2L-OS) was defined as the time from the start of 2L chemotherapy to death, while total OS was defined as the time from the start of 1L *nab*-P+GEM to death. Time to progression (TTP) on 1L treatment (1L-TTP) was defined as the interval between the start of the 1L *nab*-P+ GEM and the date disease progression was first noted. Progression-free survival (PFS) with 2L treatment (2L-PFS) was defined as the time from the start of 2L chemotherapy to subsequent disease progression or death. Data were censored if the disease had not progressed on the last evaluation or if patients were still alive at the time of data analysis (October 31, 2018). Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test.

Univariate Cox proportional hazard analysis was performed to estimate the impact of each clinicopathologic variable on 2L-OS and 2L-PFS. For these analyses, continuous variables were converted into binary variables based on their median values. Multivariate Cox analysis was further conducted to assess the simultaneous impact of various factors. Using variables with a potential significant association by univariate analysis (p \< 0.2) as well as age and gender, backward elimination was applied to identify the best independent explanatory factors. All statistical analyses were performed using IBM SPSS Statistics for Windows ver. 21.0 (IBM Corp., Armonk, NY, USA). A value of p \< 0.05 was considered statistically significant.

4. Ethical statement
--------------------

This study was approved by the Institutional Review Board of Asan Medical Center (approval number: 2017-0442). Informed consent was waived because of the retrospective design.

Results
=======

1. Patients and treatment regimens
----------------------------------

Among 203 patients who were treated with 1L *nab*-P+GEM for recurrent or metastatic pancreatic cancer, 120 patients (59.1%) received 2L chemotherapy after disease progression on 1L *nab*-P+GEM at Asan Medical Center, Seoul, Korea. Among other 83 patients, 43 and three patients did not have data on 2L chemotherapy because they were transferred to other institutions or lost to follow-up during or after progression on 1L *nab*-P+GEM, and were able to maintain primary treatment because the disease did not progress until the cutoff date, respectively; and, 25 and 12 patients did not receive 2L chemotherapy because of poor general condition and patients' refusal, respectively. The median duration of 1L treatment with *nab*-P+GEM was 6.87 months (95% CI, 6.19 to 7.55). The median age of the patients was 61 years (range, 45 to 76 years), and 70 (58.3%) were men. Most patients had a good performance status of 0 to 1 with the exception of two patients whose score was 2. Most (97.5%) received fluoropyrimidine-containing regimens as 2L chemotherapy, except for three patients who participated in clinical trials of investigational drugs ([Table 1](#t1-crt-2019-190){ref-type="table"}). Regimens were as follows: FOLFOX (58 patients, 46.7%): intravenous oxaliplatin 85 mg/m^2^, LV 400 mg/m^2^, and a 5-FU bolus 400 mg/m^2^ on day 1, followed by a 2,400 mg/m^2^ continuous 5-FU infusion over 46 hours, every 2 weeks; XELOX (22 patients, 18.3%): intravenous oxaliplatin 130 mg/m^2^ on day 1 and oral capecitabine 100 mg/m^2^ twice daily on days 1-14 every 3 weeks; Nal-IRI combined with 5-FU/LV (2 patients, 1.7%): intravenous nal-IRI 70 mg/m^2^ and LV 400 mg/m^2^, followed by a 2,400 mg/m^2^ continuous infusion of 5-FU over 46 hours, every 2 weeks; fluoropyrimidine monotherapy with S-1 (37 patients, 30.8%): oral S-1 40 mg/m^2^ twice daily on days 1-28 every 6 weeks \[[@b13-crt-2019-190]\]. FOLFIRINOX was not used as 2L chemotherapy because it was not approved for use in Korea during the study period.

2. Efficacy
-----------

None of the regimens afforded a complete response. There were eight patients with a partial response and 57 with stable disease, indicating an ORR of 6.7% (95% CI, 2.9 to 12.7) and a DCR of 54.2% (95% CI, 44.8 to 63.3). With a median follow-up of 26.27 months (range, 3.28 to 31.92 months) after starting 1L chemotherapy, 115 patients had disease progression after 2L therapy, and 101 died. The median 2L-PFS and 2L-OS among all 120 patients were 3.29 months (95% CI, 2.14 to 4.44) and 7.33 months (95% CI, 5.27 to 9.39), respectively ([Fig. 1](#f1-crt-2019-190){ref-type="fig"}). The median OS after the start of the 1L *nab*-P+GEM was 15.68 months (95% CI, 12.53 to 18.83).

When the outcomes were compared among the 2L chemotherapy regimens, there were no significant differences in efficacy between fluoropyrimidine-oxaliplatin doublet therapy and fluoropyrimidine monotherapy in terms of 2L-PFS (median, 2.89 months \[95% CI, 0.39 to 5.40\] vs. 3.81 months \[95% CI, 2.49 to 5.13\]; hazard ratio \[HR\], 0.83 \[95% CI, 0.54 to 1.28\]; p=0.40), 2L-OS (median, 7.04 months \[95% CI, 3.57 to 10.50\] vs. 7.43 months \[95% CI, 4.97 to 9.89\]; HR, 0.96 \[95% CI, 0.62 to 1.50\]; p=0.86), ORR (6.4% vs. 5.4%, p \> 0.99), and DCR (52.6% vs. 59.5%, p=0.49) ([Table 2](#t2-crt-2019-190){ref-type="table"}, [Fig. 2](#f2-crt-2019-190){ref-type="fig"}). The median OS from the start of 1L *nab*-P+GEM was 14.93 months (95% CI, 11.73 to 18.12) for patients receiving fluoropyrimidine-oxaliplatin combination treatments and 15.88 months (95% CI, 10.71 to 21.05) for patients receiving fluoropyrimidine monotherapy. There was no significant between-group differences in terms of total OS (HR, 1.16 \[95% CI, 0.75 to 1.79\]; p=0.50) ([Fig. 3](#f3-crt-2019-190){ref-type="fig"}).

3. Third-line chemotherapy
--------------------------

Among 115 patients with progression on 2L chemotherapy, 53 (46.1%) subsequently had third-line (3L) chemotherapy. There was no significant difference in the frequency of 3L treatment between patients whose disease progressed on 2L fluoropyrimidine-oxaliplatin doublets (38/77, 49.4%) versus those on fluoropyrimidine monotherapy (14/34, 41.2%) (p=0.43). After progression on 2L fluoropyrimidine-oxaliplatin doublet regimens, fluoropyrimidine monotherapy was the most frequently used 3L chemotherapy (31/38, 81.6%), followed by nal-IRI plus 5-FU/LV (4/38, 10.5%). Most patients whose disease progressed on fluoropyrimidine monotherapy received a 3L oxaliplatin doublet regimen (12/14, 85.7%), and two patients (2/14, 14.3%) received nal-IRI plus 5-FU/LV ([S1 Table](#SD1-crt-2019-190){ref-type="supplementary-material"}).

4. Prognostic factors for survival with 2L chemotherapy
-------------------------------------------------------

On univariate analysis, factors significantly associated with a poor 2L-OS included a high NLR (\> median \[2.2\]), high PLR (\> median \[154.4\]), ≥ 2 organs with metastases, presence of liver metastasis, and a short 1L-TTP (≤ median \[6.4 months\]). On multivariate analysis, high NLR (\> 2.2; HR, 1.58; 95% CI, 1.05 to 2.39; p=0.03) and a short 1L-TTP (≤ 6.4; HR, 1.57; 95% CI, 1.05 to 2.36; p=0.03) were independent predictors of a poor 2L-OS2 ([Table 3](#t3-crt-2019-190){ref-type="table"}). For 2L-PFS, the presence of liver metastasis (HR, 1.51; 95% CI, 1.03 to 2.23; p=0.04 and adjusted HR, 1.51; 95% CI, 1.02 to 2.24; p=0.04) was the only statistically significant factor on both univariate and multivariate analyses ([S2 Table](#SD2-crt-2019-190){ref-type="supplementary-material"}). There was no difference in these prognostic factors between patients receiving fluoropyrimidine-oxaliplatin doublets and those treated with fluoropyrimidine monotherapy ([S3 Table](#SD3-crt-2019-190){ref-type="supplementary-material"}).

Discussion
==========

This study showed that 59.1% of patients with mPDAC treated with 1L *nab*-P+GEM subsequently received 2L chemotherapy, most commonly fluoropyrimidine-based chemotherapy. The median 2L-PFS and 2L-OS with 2L therapy after progression on 1L *nab*-P+GEM were 3.29 months and 7.33 months, respectively. Our findings are consistent with the results of *post-hoc* analysis for patients enrolled in the MPACT trial, in which 40% of patients assigned to the *nab*-P+GEM arm subsequently had 2L therapy resulting in a median OS of 5.3 months (95% CI, 4.17 to 5.78) \[[@b14-crt-2019-190]\]. Our results are also comparable in terms of total OS from the start of 1L *nab*-P+ GEM. The median was 15.68 months (95% CI, 12.53 to 18.83) in our cohort and 12.8 months (95% CI, 10.9 to 14.2) in the MPACT *post-hoc* analysis \[[@b14-crt-2019-190]\]. Our survival outcomes with 2L chemotherapy are in line with the results of previous phase III trials for 2L chemotherapy (PFS, 1.5 to 3.1 months; OS, 3.3 to 9.9 months) after failure of gemcitabine-based chemotherapy conducted prior to the establishment of the 1L *nab*-P+GEM regimen \[[@b9-crt-2019-190]-[@b11-crt-2019-190]\].

Although fluoropyrimidine-based chemotherapy is recommended as 2L therapy after progression on 1L *nab*-P+GEM, this continues to be debated. At present, FOLFIRINOX, fluoropyrimidine-oxaliplatin doublets such as FOLFOX or oxaliplatin plus LV and 5-FU (OFF), nal-IRI plus 5-FU/LV, and fluoropyrimidine monotherapy such as 5-FU/LV, capecitabine, or S-1 are available as 2L chemotherapy after failure of 1L gemcitabine-based therapy. S-1, an oral fluoropyrimidine, is approved for the treatment of advanced PDAC in East Asia based on the non-inferiority of S-1 compared with gemcitabine monotherapy as 1L therapy in the randomized phase III GEST trial \[[@b15-crt-2019-190]\]. Fluoropyrimidine-oxaliplatin regimens have been widely used since the OFF regimen (oxaliplatin 85 mg/m^2^ before LV 200 mg/m^2^, followed by a continuous infusion of 5-FU 2,000 mg/m^2^ over 24 hours on days 8 and 22) showed a significantly better OS than 5-FU/LV (LV 200 mg/m^2^ followed by a continuous infusion of 5-FU 2,000 mg/m^2^ over 24 hours on days 1, 8, 15, and 22) in the phase III CONKO-003 trial \[[@b9-crt-2019-190]\]. However, Japanese phase II trial comparing S-1 plus oxaliplatin with S-1 alone and the recent phase III PANCREOX study with a more commonly used biweekly administration schedule (mFOLFOX6: oxaliplatin 85 mg/m^2^ plus LV 400 mg/m^2^ and 400 mg/m^2^ of bolus FU followed by 2,400 mg/m^2^ of 5-FU continuous infusion for 46 hours, every 14 days vs. biweekly LV 400 mg/m^2^ and a 400 mg/m^2^ of bolus FU followed by 2,400 mg/m^2^ of 5-FU continuous infusion for 46 hours, every 14 days) failed to show a clinical benefit with the addition of oxaliplatin to fluoropyrimidine \[[@b10-crt-2019-190],[@b16-crt-2019-190]\]. The nal-IRI plus 5-FU/LV regimen is the newest option for patients with mPDAC that progresses on 1L gemcitabine, as indicated by its success in the NAPOLI-1 trial \[[@b11-crt-2019-190]\].

In the current study, there was no significant difference in efficacy between fluoropyrimidine-oxaliplatin doublets and fluoropyrimidine monotherapy for 2L salvage treatment. This finding is in line with the results of the Japanese Phase II trial \[[@b16-crt-2019-190]\] and PANCREOX trial \[[@b10-crt-2019-190]\], but in contrast to those of the CONKO-003 trial \[[@b9-crt-2019-190]\]. Discrepancies in the efficacy of oxaliplatin reported among the studies may be attributed to the heterogeneous baseline characteristics of the different patient populations as well as differences in study design or dosing schedules. Oxaliplatin-containing chemotherapy may have limitations as 2L therapy after progression on 1L *nab*-P+ GEM in terms of tolerability considering that a substantial proportion of patients treated with *nab*-P+GEM suffer from neuropathy. Although oxaliplatin-containing triplet chemotherapy (i.e., FOLFIRINOX) as 2L chemotherapy may have better clinical outcomes in medically fit patients with mPDAC, we could not evaluate that question in our study, as no patient in the study cohort was treated with 2L FOLFIRINOX. Considering the relatively high risk of toxicities with FOLFIRINOX, it is unlikely to be universally accepted as 2L therapy after 1L *nab*-P+GEM. Further studies are needed to elucidate the clinical relevance of 2L oxaliplatin-containing chemotherapy following 1L *nab*-P+Gem for mPDAC.

Irinotecan-fluoropyrimidine doublets have also been investigated in patients with mPDAC \[[@b17-crt-2019-190]\]. While combining fluoropyrimidine with conventional irinotecan did not show a clear clinical benefit, nal-IRI plus 5-FU/LV significantly improved survival compared with 5-FU/LV, and this regimen received regulatory approval. Recent real-world data showed consistent clinical outcomes with nal-IRI plus 5-FU/LV in patients with mPDAC who had previously received gemcitabine-based chemotherapy \[[@b18-crt-2019-190],[@b19-crt-2019-190]\]. Because of the heterogeneity of 1L chemotherapy prior to the administration of nal-IRI plus 5-FU/LV and different treatment lines (from 1st- to 5th-line) when it was used in those studies, however, it is difficult to estimate the efficacy of 2L nal-IRI plus 5-FU/LV after 1L *nab*-P+GEM. We also could not evaluate its efficacy due to the small number of patients in our study who had been treated with 2L nal-IRI plus 5-FU/LV.

Of note, the median survival in our cohort of more than 15 months after starting 1L therapy suggests that effective 2L chemotherapy after 1L *nab*-P+GEM may lead to a relatively long-term survival in patients with mPDAC. Our analysis showed that 59.1% of patients with 1L *nab*-P+GEM could receive 2L therapy and subsequent 3L chemotherapy was given in 49.1% of 2L patient population. Although our analysis is limited to discuss the overall outcomes of 1L *nab*-P+ GEM, because we included only 2L population, current findings may indicate that subsequent 2L and 3L chemotherapy may prolong the survival of patients with mPDAC who started 1L *nab*-P+GEM. Although there is no head-to-head comparative trial, FOLFIRINOX showed numerically better survival outcomes compared to *nab*-P+GEM in 1L setting \[[@b2-crt-2019-190],[@b3-crt-2019-190]\], recent retrospective analyses and meta-analysis in real-world setting have revealed that survival outcomes with these regimens may be similar in mPDAC patients \[[@b4-crt-2019-190],[@b20-crt-2019-190]\]. The efficacy of subsequent 2L and 3L chemotherapy after progression on 1L *nab*-P+GEM shown in our study may contribute to these results. However, it is still difficult to clearly demonstrate the contribution of 2L chemotherapy after nab-P+GEM with the current data alone. Considerable work is needed to fully understand the implications of subsequent chemotherapy and to determine appropriate salvage therapy strategy.

The NLR at the start of 2L chemotherapy was shown to be predictive of 2L-OS in our cohort. Consistent with ourresults, although the underlying mechanism is not yet known, a high NLR has been suggested as a poor prognostic factor for patients with pancreatic cancer \[[@b21-crt-2019-190]-[@b23-crt-2019-190]\]. Multivariate *post-hoc* analysis of the MPACT trial revealed that an NLR ≤ 5 at the end of 1L gemcitabine-based therapy was associated with longer post-1L survival \[[@b14-crt-2019-190]\], which is also compatible with our findings. Moreover, a long 1L-PFS (≥ 4.4 months) in that analysis was also associated with longer survival. This is consistent with our finding that a short TTP after 1L *nab*-P+GEM therapy (≤ 6.4 months) was associated with poor 2L-OS.

This study is limited by being a single-center study and by its retrospective design. Another limitation is the heterogeneity of the 2L regimens used. These were chosen by attending physicians based not only individual patients' clinical factors but also on reimbursement policies in Korea. However, the fact that all patients in the study had received the same, new 1L regimen made our cohort more homogenous, and this is the first real-world study evaluating outcomes of salvage treatment for mPDAC previously treated with *nab*-P+GEM.

In conclusion, 2L fluoropyrimidine monotherapy and fluoropyrimidine-oxaliplatin doublets after failure of 1L *nab*-P+GEM had modest efficacy. There was no difference in efficacy outcomes between fluoropyrimidine-oxaliplatin doublet chemotherapy and fluoropyrimidine monotherapy. Further investigation is warranted for the optimal 2L chemotherapy regimens and sequencing of systemic chemotherapy for patients with mPDAC in multicenter prospective trials.
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Third-line chemotherapy regimen according to the prior second-line chemotherapy

###### 

Univariate and multivariate analysis of progression-free survival for second-line chemotherapy

###### 

Baseline patients' characteristics according to the second-line chemotherapy
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![Progression-free survival (PFS) (A) and overall survival (OS) (B) with second-line chemotherapy after progression on *nab*-paclitaxel plus gemcitabine (*nab*-P+GEM). 2L, second-line; CI, confidence interval.](crt-2019-190f2){#f2-crt-2019-190}

![Overall survival (OS) from the start of first-line *nab*-paclitaxel plus gemcitabine (*nab*-P+GEM) according to the second-line chemotherapy regimen. CI, confidence interval.](crt-2019-190f3){#f3-crt-2019-190}

###### 

Baseline characteristics of patients with metastatic pancreatic ductal adenocarcinoma

                                    No. (%) (n=120)
  --------------------------------- -------------------
  **Sex**                           
   Male                             70 (58.3)
   Female                           50 (41.7)
  **Age, median (range, yr)**       61 (35-79)
  **ECOG performance status**       
   0                                44 (36.7)
   1                                74 (61.7)
   2                                2 (1.7)
  **No. of metastatic sites**       
   0                                4 (3.3)
   1                                59 (49.2)
   2                                34 (28.3)
   3                                16 (13.3)
   4                                7 (5.8)
  **Site of metastasis**            
   Liver                            71 (59.2)
   Lung                             30 (25.0)
   Bone                             7 (5.8)
   Peritoneum                       46 (38.3)
   Lymph nodes                      40 (33.3)
  **1L-TTP, median (95% CI, mo)**   6.87 (0.49-22.45)
  **2L chemotherapy regimens**      
   FOLFOX                           56 (46.7)
   XELOX                            22 (18.3)
   S-1                              37 (30.8)
   Nal-IRI+5-FU/LV                  2 (1.7)
   Investigational drugs            3 (2.5)

ECOG, Eastern Cooperative Oncology Group; 1L, first line; 2L, second line; TTP, time to progression; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; XELOX, capecitabine plus oxaliplatin, S-1, tegafur/gimeracil/oteracil; Nal-IRI+5-FU/LV, liposomal irinotecan plus fluorouracil and leucovorin.

###### 

Treatment outcomes with second-line chemotherapy

                                     Fluoropyrimidine-oxaliplatin doublets (n=78)   Fluoropyrimidine monotherapy (n=37)   p-value
  ---------------------------------- ---------------------------------------------- ------------------------------------- ---------
  **Response, n (%)**                                                                                                     
   Partial response (PR)             5 (6.4)                                        2 (5.4)                               
   Stable disease (SD)               36 (46.2)                                      20 (54.1)                             
   Progressive disease (PD)          37 (47.4)                                      15 (40.5)                             
  **ORR (CR+PR) (95% CI, %)**        6.4 (2.1-14.3)                                 5.4 (0.7-18.2)                        1.00
  **DCR (CR+PR+SD) (95% CI, %)**     52.6 (40.9-64.0)                               59.5 (42.1-75.2)                      0.49
  **Survival**                                                                                                            
   2L-PFS, months, median (95% CI)   2.89 (0.39-5.40)                               3.81 (2.49-5.13)                      0.40
   2L-OS, months, median (95% CI)    7.04 (3.57-10.50)                              7.43 (4.97-9.89)                      0.86

ORR, overall response rate; CR, complete response; CI, confidence interval; DCR, disease control rate; 2L-PFS, progression-free survival for second-line treatment; 2L-OS, overall survival for second-line treatment.

###### 

Univariate and multivariate analysis of overall survival with second-line chemotherapy

                                                 Univariate analysis   Multivariate analysis                      
  ---------------------------------------------- --------------------- ----------------------- ------------------ ------
  **Sex**                                                                                                         
   Male                                          Reference                                     \-                 \-
   Female                                        0.94 (0.63-1.41)      0.77                    \-                 \-
  **Initial disease status**                                                                                      
   Recurrent                                     Reference                                     \-                 \-
   Metastatic                                    1.09 (0.70-1.69)      0.70                    \-                 \-
  **Age (yr)**                                                                                                    
   ≤ 60                                          Reference                                     \-                 \-
   \> 60                                         0.88 (0.59-1.31)      0.52                    \-                 \-
  **ECOG performance status**                                                                                     
   0                                             Reference                                     \-                 \-
   1-2                                           1.46 (0.96-2.20)      0.08                    \-                 \-
  **CA19-9**                                                                                                      
   Normal                                        Reference                                     \-                 \-
   Elevated                                      1.12 (0.63-1.99)      0.70                    \-                 \-
  **Albumin**                                                                                                     
   Normal                                        Reference                                     \-                 \-
   Decreased                                     1.16 (0.78-1.73)      0.46                    \-                 \-
  **NLR**                                                                                                         
   ≤ 2.2                                         Reference                                     Reference          
   \> 2.2                                        1.78 (1.19-2.66)      \< 0.01                 1.58 (1.05-2.38)   0.03
  **PLR**                                                                                                         
   ≤ 154.4                                       Reference                                     \-                 \-
   \> 154.4                                      1.57 (1.05-2.36)      0.03                    \-                 \-
  **No. of metastatic sites**                                                                                     
   0-1                                           Reference                                     Reference          
   ≥ 2                                           1.60 (1.07-2.38)      0.02                    1.48 (0.99-2.22)   0.06
  **Presence of liver metastasis**                                                                                
   No                                            Reference                                     \-                 \-
   Yes                                           1.77 (1.16-2.69)      \< 0.01                 \-                 \-
  **Presence of lung metastasis**                                                                                 
   No                                            Reference                                     \-                 \-
   Yes                                           0.97 (0.62-1.52)      0.88                    \-                 \-
  **Presence of bone metastasis**                                                                                 
   No                                            Reference                                     \-                 \-
   Yes                                           2.05 (0.943-4.44)     0.07                    \-                 \-
  **Presence of peritoneal metastasis**                                                                           
   No                                            Reference                                     \-                 \-
   Yes                                           0.99 (0.66-1.49)      0.95                    \-                 \-
  **Presence of lymph nodes metastasis**                                                                          
   No                                            Reference                                     \-                 \-
   Yes                                           1.15 (0.76-1.73)      0.51                    \-                 \-
  **1L-TTP (mo)**                                                                                                 
   ≤ 6.4                                         1.68 (1.13-2.52)      0.01                    1.57 (1.05-2.36)   0.03
   \> 6.4                                        Reference                                     Reference          
  **Best response for first-line *nab*-P+GEM**                                                                    
   CR/PR/SD                                      Reference                                     \-                 \-
   PD                                            1.38 (0.83-2.31)      0.22                    \-                 \-
  **Second-line regimen**                                                                                         
   Fluoropyrimidine monotherapy                  Reference                                     \-                 \-
   Fluoropyrimidine-oxaliplatin doublets         0.96 (0.62-1.50)      0.86                    \-                 \-

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; 1L, first line; TTP, time to progression; *nab*-P+GEM, *nab*-paclitaxel plus gemcitabine; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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